|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Cancer Institute (NCI) |
|---|---|
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00019149 |
Purpose
RATIONALE: Evaluating patients who have skin diseases may help doctors plan more effective treatment and follow-up for skin diseases and systemic diseases that show up in the skin.
PURPOSE: This clinical trial is studying and following patients with skin diseases.
| Condition | Intervention |
|---|---|
|
Lymphoma Melanoma (Skin) |
Genetic: polymerase chain reaction Other: electron microscopy Other: flow cytometry Other: fluorescent antibody technique Other: immunoenzyme technique Other: immunohistochemistry staining method Other: microscopy Procedure: biopsy Procedure: radiography |
| Study Type: | Interventional |
| Study Design: | Diagnostic, Open Label |
| Official Title: | Evaluation and Treatment of Subjects With Dermatologic Diseases |
| Estimated Enrollment: | 500 |
| Study Start Date: | June 1996 |
| Estimated Primary Completion Date: | December 2016 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
Secondary
OUTLINE: Samples of blood, urine, stool, exudates, skin scrapings, hair, and nails are collected from patients and then are analyzed, as medically indicated, using the following diagnostic tests:
Immunopathologic tests, including:
PROJECTED ACCRUAL: A total of 500 patients will be accrued for this study.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
Contacts and Locations| United States, Maryland | |
| Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office | Recruiting |
| Bethesda, Maryland, United States, 20892-1182 | |
| Contact: Patient Recruitment 888-NCI-1937 | |
| Study Chair: | Mark C. Udey, MD, PhD | NCI - Dermatology Branch |
More Information
| Study ID Numbers: | CDR0000064802, NCI-96-C-0102 |
| Study First Received: | July 11, 2001 |
| Last Updated: | February 11, 2009 |
| ClinicalTrials.gov Identifier: | NCT00019149 History of Changes |
| Health Authority: | Unspecified |
|
stage I cutaneous T-cell non-Hodgkin lymphoma stage II cutaneous T-cell non-Hodgkin lymphoma stage III cutaneous T-cell non-Hodgkin lymphoma stage IV cutaneous T-cell non-Hodgkin lymphoma stage I melanoma stage II melanoma stage III melanoma |
stage IV melanoma stage 0 melanoma stage I mycosis fungoides/Sezary syndrome stage II mycosis fungoides/Sezary syndrome stage III mycosis fungoides/Sezary syndrome stage IV mycosis fungoides/Sezary syndrome |
|
Neoplasms by Histologic Type Immunoproliferative Disorders Immune System Diseases Neoplasms, Nerve Tissue Melanoma Neuroendocrine Tumors Lymphatic Diseases |
Neuroectodermal Tumors Neoplasms Neoplasms, Germ Cell and Embryonal Nevi and Melanomas Lymphoproliferative Disorders Lymphoma |